Display options
Cite
Lemercier CE, Schulz SB, Heidmann KE, et al. Dopamine D3 Receptors Inhibit Hippocampal Gamma Oscillations by Disturbing CA3 Pyramidal Cell Firing Synchrony. Front Pharmacol. 2016;6:297doi: 10.3389/fphar.2015.00297.
Lemercier, C. E., Schulz, S. B., Heidmann, K. E., Kovács, R., & Gerevich, Z. (2015). Dopamine D3 Receptors Inhibit Hippocampal Gamma Oscillations by Disturbing CA3 Pyramidal Cell Firing Synchrony. Frontiers in pharmacology, 6297. https://doi.org/10.3389/fphar.2015.00297
Lemercier, Clément E, et al. "Dopamine D3 Receptors Inhibit Hippocampal Gamma Oscillations by Disturbing CA3 Pyramidal Cell Firing Synchrony." Frontiers in pharmacology vol. 6 (2015): 297. doi: https://doi.org/10.3389/fphar.2015.00297
Lemercier CE, Schulz SB, Heidmann KE, Kovács R, Gerevich Z. Dopamine D3 Receptors Inhibit Hippocampal Gamma Oscillations by Disturbing CA3 Pyramidal Cell Firing Synchrony. Front Pharmacol. 2016 Jan 06;6:297. doi: 10.3389/fphar.2015.00297. eCollection 2015. PMID: 26779018; PMCID: PMC4702013.
Copy Download .nbib Format: NLM
Share it on

Front Pharmacol. 2016 Jan 06;6:297. doi: 10.3389/fphar.2015.00297. eCollection 2015.

Dopamine D3 Receptors Inhibit Hippocampal Gamma Oscillations by Disturbing CA3 Pyramidal Cell Firing Synchrony.

Frontiers in pharmacology

Clément E Lemercier, Steffen B Schulz, Karin E Heidmann, Richard Kovács, Zoltan Gerevich

Affiliations

  1. Institute of Neurophysiology, Charité - Universitätsmedizin Berlin Berlin, Germany.

PMID: 26779018 PMCID: PMC4702013 DOI: 10.3389/fphar.2015.00297

Abstract

Cortical gamma oscillations are associated with cognitive processes and are altered in several neuropsychiatric conditions such as schizophrenia and Alzheimer's disease. Since dopamine D3 receptors are possible targets in treatment of these conditions, it is of great importance to understand their role in modulation of gamma oscillations. The effect of D3 receptors on gamma oscillations and the underlying cellular mechanisms were investigated by extracellular local field potential and simultaneous intracellular sharp micro-electrode recordings in the CA3 region of the hippocampus in vitro. D3 receptors decreased the power and broadened the bandwidth of gamma oscillations induced by acetylcholine or kainate. Blockade of the D3 receptors resulted in faster synchronization of the oscillations, suggesting that endogenous dopamine in the hippocampus slows down the dynamics of gamma oscillations by activation of D3 receptors. Investigating the underlying cellular mechanisms for these effects showed that D3 receptor activation decreased the rate of action potentials (APs) during gamma oscillations and reduced the precision of the AP phase coupling to the gamma cycle in CA3 pyramidal cells. The results may offer an explanation how selective activation of D3 receptors may impair cognition and how, in converse, D3 antagonists may exert pro-cognitive and antipsychotic effects.

Keywords: antipsychotics; cognition; dopamine D3 receptors; gamma rhythm; hippocampus CA3 region; schizophrenia

References

  1. Neuron. 2007 Oct 4;56(1):141-54 - PubMed
  2. Neurosci Lett. 2010 Sep 13;481(3):149-53 - PubMed
  3. Cereb Cortex. 2005 Jul;15(7):1016-24 - PubMed
  4. J Neurosci. 2008 Jul 23;28(30):7679-86 - PubMed
  5. Hippocampus. 2008;18(5):492-502 - PubMed
  6. Proc Natl Acad Sci U S A. 2012 Aug 7;109(32):13118-23 - PubMed
  7. Biol Psychiatry. 2006 Dec 1;60(11):1231-40 - PubMed
  8. Mol Psychiatry. 2012 Dec;17(12):1206-27 - PubMed
  9. Nature. 2006 Feb 9;439(7077):733-6 - PubMed
  10. Pharmacol Biochem Behav. 1999 Jun;63(2):201-11 - PubMed
  11. Neuroscience. 1991;41(1):1-24 - PubMed
  12. Am J Med Genet B Neuropsychiatr Genet. 2004 Jan 1;124B(1):1-5 - PubMed
  13. Neuron. 2010 Nov 4;68(3):500-11 - PubMed
  14. Eur Neuropsychopharmacol. 2009 Jan;19(1):23-33 - PubMed
  15. Schizophr Res. 2010 Jun;119(1-3):191-7 - PubMed
  16. J Comp Neurol. 1998 Dec 21;402(3):353-71 - PubMed
  17. Front Syst Neurosci. 2013 Oct 30;7:74 - PubMed
  18. Nature. 1998 Jul 9;394(6689):186-9 - PubMed
  19. Brain Res Mol Brain Res. 1995 Oct;33(1):97-103 - PubMed
  20. Front Hum Neurosci. 2014 Sep 30;8:742 - PubMed
  21. J Physiol. 1995 Sep 15;487 ( Pt 3):583-600 - PubMed
  22. J Clin Psychopharmacol. 2008 Feb;28(1):45-51 - PubMed
  23. Eur J Pharmacol. 2011 Sep;666(1-3):43-52 - PubMed
  24. Eur J Neurosci. 2009 Jan;29(2):319-27 - PubMed
  25. Neuropharmacology. 2012 Feb;62(2):914-24 - PubMed
  26. Neuropsychopharmacology. 2012 Feb;37(3):770-86 - PubMed
  27. Br J Pharmacol. 2012 Dec;167(7):1480-91 - PubMed
  28. Neuron. 2013 Mar 20;77(6):1002-16 - PubMed
  29. Int J Psychophysiol. 2011 Jan;79(1):55-63 - PubMed
  30. Biol Psychiatry. 2006 Sep 15;60(6):570-7 - PubMed
  31. Nat Rev Neurosci. 2010 Feb;11(2):100-13 - PubMed
  32. Arch Gen Psychiatry. 1999 Nov;56(11):1001-5 - PubMed
  33. Brain Res. 1991 Nov 15;564(2):203-19 - PubMed
  34. Neuropsychologia. 2006;44(10):1663-73 - PubMed
  35. J Neurosci. 2004 Oct 27;24(43):9658-68 - PubMed
  36. Nat Rev Drug Discov. 2012 Feb 01;11(2):141-68 - PubMed
  37. Epilepsia. 2012 Nov;53(11):1978-86 - PubMed
  38. Naunyn Schmiedebergs Arch Pharmacol. 2013 Feb;386(2):155-66 - PubMed
  39. Psychiatr Genet. 2003 Mar;13(1):1-12 - PubMed
  40. Physiol Rev. 1998 Jan;78(1):189-225 - PubMed
  41. Prog Med Chem. 2010;49:37-80 - PubMed
  42. Neuropsychopharmacology. 2011 Mar;36(4):887-95 - PubMed
  43. Eur Neuropsychopharmacol. 2013 Aug;23(8):799-813 - PubMed
  44. Psychopharmacology (Berl). 2005 May;179(3):567-75 - PubMed
  45. Arch Gen Psychiatry. 1997 Mar;54(3):225-32 - PubMed
  46. Eur J Neurosci. 2015 Jan;41(1):31-44 - PubMed
  47. Eur J Pharmacol. 1997 Apr 18;324(2-3):147-51 - PubMed
  48. J Neurosci. 2010 Nov 10;30(45):15134-45 - PubMed
  49. J Pharmacol Exp Ther. 2010 Apr;333(1):328-40 - PubMed
  50. PLoS One. 2014 May 06;9(5):e95871 - PubMed
  51. Neuron. 2010 Feb 25;65(4):541-9 - PubMed

Publication Types